Vilfuro-G combines vilanterol, fluticasone furoate and glycopyrronium bromide, for the long-term management and treatment of moderate to severe chronic obstructive pulmonary (COPD) disease. The product is available in a single-strength fixed dose, with a recommended once-daily dosage.
Nilesh Gupta, MD, Lupin said, ?We are delighted to introduce Vilfuro-G, a testament to our commitment to our patients and our focus on innovation. This milestone reinforces our resolve to expanding our respiratory portfolio, providing COPD patients with access to healthcare solutions, and transforming lives.?
Rajeev Sibal, President India region formulations, Lupin, added, ?As the global prevalence of COPD continues to surge, India bears a significant 18% of this disease burden. With our extensive respiratory portfolio and the approval of Vilfuro-G, we take immense pride in offering healthcare professionals and patients with innovative treatment solutions.?
Lupin is a leading manufacturer of active pharmaceutical ingredients (APIs) in India and a key supplier to global bodies and governments in more than 70 countries.
The pharmaceutical company?s consolidated net profit zoomed to Rs 495.32 crore in Q2 FY24 as against Rs 134.47 crore recorded in Q2 FY23. Revenue from operations rose 20.7% YoY to Rs 4,939.23 crore in Q2 FY24.
The scrip declined 2.48% to Rs 1,188.65 on the BSE.
Powered by Capital Market - Live News